Skip to content

Retatrutide: FDA approval status and what the trials have shown

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Retatrutide is an investigational once-weekly medicine from Lilly, and it is not FDA-approved. Lilly has said it plans to submit it to FDA in the first quarter of 2027. In the TRIUMPH-1 trial, Lilly reported average weight loss of 28.3% at 80 weeks on the 12 mg dose. FDA says retatrutide cannot be used in compounding.

Source: Eli Lilly

Key takeaways

  • Retatrutide is not FDA-approved, and Lilly says it can't be legally sold or marketed for human use.
  • Lilly plans to submit it in the first quarter of 2027. A submission is not an approval.
  • The trial doses name study groups. They are not dosing guidance, and no approved dose exists.
  • FDA says retatrutide can't be compounded and urges consumers not to buy "research use" products.
  • If you're deciding about treatment now, the choice is among approved medicines, with your prescriber.

Retatrutide is the pipeline medicine people search for most, and there’s a wide gap between the headlines and its legal status. This page gives the status first, then each published result with its date and context. Everything about the trials comes from Eli Lilly’s own announcements and the ClinicalTrials.gov registry. Company press releases are not FDA findings, and no FDA review of these data has been reported.

Retatrutide FDA approval status

  • Not FDA-approved. In Lilly’s words: “Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use.”
  • Submission planned for the first quarter of 2027. Lilly has said it “is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.” A BLA is the company’s formal request for FDA approval.
  • No approval date. A plan to submit is a company statement about timing. Lilly’s announcement says there is no guarantee that planned or ongoing studies will be completed as planned, that future results will be consistent with results to date, or that retatrutide will receive regulatory approval.

FDA’s own statement is short: retatrutide and cagrilintide “are not components of FDA-approved drugs and have not been found safe and effective for any condition.”

What retatrutide is and what it does

Lilly calls it an investigational, once-weekly, triple hormone receptor agonist. It’s a single molecule that switches on the receptors for three hormones: GIP, GLP-1 and glucagon. The approved Lilly medicines on this site are different molecules with their own labels. Retatrutide has no label.

The TRIUMPH program

The first Phase 3 program is called TRIUMPH. Phase 3 trials are the large, late-stage studies that usually come before a company asks FDA for approval. Lilly says it is testing retatrutide across four global registrational trials, for obesity or overweight, for moderate-to-severe obstructive sleep apnea with obesity, and for knee osteoarthritis pain. The program began in 2023 and enrolled more than 5,800 participants.

ClinicalTrials.gov lists TRIUMPH-1 (NCT05929066) as a Phase 3 study sponsored by Eli Lilly and Company. Its overall status is Completed, its primary completion date was April 6, 2026, and its actual enrollment was 2,335.

Phase 3 results, in date order

TRIUMPH-4, reported December 11, 2025

This trial was in adults with obesity or overweight and knee osteoarthritis, without diabetes. Lilly noted that 84.0% of participants started with a BMI of 35 or more. Both doses studied met all primary and key secondary endpoints, the main goals set for the trial, at 68 weeks. For the two main goals, retatrutide lowered weight by up to an average of 28.7% (71.2 lbs) and reduced pain by up to an average of 4.5 points (75.8%) on the WOMAC pain score.

TRIUMPH-1, reported May 21, 2026

This trial was in adults with obesity or overweight and a weight-related comorbidity (a health problem linked to weight), without diabetes. Lilly called it the pivotal obesity trial. At 80 weeks, on the efficacy estimand, which estimates the result if everyone had kept taking the medicine as planned:

  • 4 mg: an average of 47.2 lbs (19.0%)
  • 9 mg: an average of 64.4 lbs (25.9%)
  • 12 mg: an average of 70.3 lbs (28.3%)

In a blinded extension planned in advance for people with a BMI of 35 or more, those who stayed on 12 mg to 104 weeks lost an average of 85.0 lbs (30.3%).

The same announcement gives the treatment-regimen estimand, which counts everyone whether or not they kept taking it. On that measure, body weight at 80 weeks changed by -17.6% on 4 mg, -23.7% on 9 mg and -25.0% on 12 mg, against -3.9% on placebo.

The share of people who stopped because of adverse events was 4.1%, 6.9% and 11.3% with retatrutide 4 mg, 9 mg and 12 mg, compared with 4.9% with placebo.

TRIUMPH-2, reported July 23, 2026

This trial was in adults with type 2 diabetes and obesity or overweight. At 80 weeks, participants lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%) and 49.6 lbs (20.8%) across the three doses studied, along with A1C reductions of up to an average of 1.6%. A1C is a blood test that reflects average blood sugar over the past few months.

TRIUMPH-3, reported July 23, 2026

This trial was in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Participants lost up to an average of 55.8 lbs (22.6%) at 80 weeks.

The heart findings need care. Lilly said major adverse cardiovascular events happened less often than expected in both the retatrutide and placebo groups. On the broader five-part measure, there were 44 events on retatrutide and 52 on placebo, a hazard ratio of 0.82. On the narrower three-part measure (cardiovascular death, heart attack or stroke), there were 27 events on retatrutide and 23 on placebo, a hazard ratio of 1.12. The reported confidence intervals for both span 1, which means neither result rules out no difference between the groups.

TRANSCEND-T2D-2: retatrutide against Ozempic, reported October 28, 2026

TRANSCEND is a second Phase 3 program, in type 2 diabetes. TRANSCEND-T2D-2 compared retatrutide 9 mg and 12 mg with Ozempic 2 mg, the highest approved Ozempic dose, in 1,298 adults with type 2 diabetes not controlled on metformin, with or without an SGLT2 inhibitor. At 80 weeks, both retatrutide doses lowered A1C by an average of 2.2%, against 1.8% with Ozempic. Participants lost an average of 44.3 lbs (19.5%) on 9 mg and 47.4 lbs (20.9%) on 12 mg, against 20.9 lbs (9.4%) on Ozempic.

Two cautions. The trial was open-label, which means participants and their doctors knew which medicine each person took. And these are topline results from Lilly’s press release, not an FDA review.

How to read these numbers

The doses above name the trial groups. They are not dosing guidance, and no approved dose of retatrutide exists.

The percentages are averages. “Up to” figures describe the highest-performing dose group. The efficacy estimand and the treatment-regimen estimand answer different questions, and in TRIUMPH-1 the second gives lower figures.

Don’t set these results against the label figures of approved medicines, or against each other. The four trials enrolled different people for different lengths of time. The stopping rates above are not the full side-effect picture. A complete safety profile comes with an FDA label, and retatrutide doesn’t have one.

Buying retatrutide before approval

There is no legal source for consumers. FDA says retatrutide cannot be used in compounding under federal law. It has warned companies that illegally sold unapproved drugs containing retatrutide falsely labeled “for research purposes” or “not for human consumption.” FDA noted these products were sold straight to consumers for human use, with dosing instructions. FDA “urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”

We don’t name, link to or list prices for any seller of retatrutide. The compounded GLP-1 page explains FDA’s rules in more depth.

What happens next

The next step Lilly has announced is its planned submission in the first quarter of 2027. Lilly or FDA would announce a submission, an acceptance for review, a decision or new trial results. Their own pages are the place to confirm where retatrutide stands.

If you’re deciding about treatment, the choice is among medicines that are approved. The pipeline overview covers the other investigational medicines, and the conditions overview lists what each approved GLP-1 is for. Whether to start an approved medicine or wait is a conversation for you and your prescriber.

Frequently asked questions

Is retatrutide FDA approved?

No. Lilly calls retatrutide an investigational molecule that cannot be legally sold or marketed for human use. FDA says retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition. Lilly has said it plans to submit retatrutide for US approval in the first quarter of 2027.

When will retatrutide be approved?

There is no approval date, and we don't predict one. The only timing the company has given is its plan to submit a Biologics License Application, its formal request for approval, in the first quarter of 2027. FDA review comes after a submission. Lilly itself says there is no guarantee retatrutide will receive regulatory approval.

What were the retatrutide Phase 3 weight loss results?

In TRIUMPH-1, in adults with obesity or overweight without diabetes, Lilly reported average weight loss at 80 weeks of 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, using the efficacy estimand. Counting everyone regardless of whether they kept taking it, the changes were -17.6%, -23.7% and -25.0%, against -3.9% on placebo.

Can I buy retatrutide?

Not legally. Lilly says retatrutide cannot be legally sold or marketed for human use, and FDA says it cannot be used in compounding under federal law. FDA has warned companies that sold unapproved retatrutide falsely labeled for research purposes. It urges consumers not to buy such products, which are of unknown quality and may be harmful.

What is retatrutide and what does it do?

Lilly calls retatrutide an investigational, once-weekly, triple hormone receptor agonist. That means a single molecule that switches on the body's receptors for three hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. It is being studied in the TRIUMPH Phase 3 program, which began in 2023.

Sources (13)

  1. 1.
    Eli Lilly: Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
    “In the TRANSCEND-T2D-2 trial, both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks. Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic. [...] TRANSCEND-T2D-2 (NCT06260722) is a Phase 3, randomized, open-label trial comparing once-weekly retatrutide (9 mg and 12 mg) with once-weekly Ozempic 2 mg in 1,298 adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor.”
  2. 2.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “Retatrutide is an investigational, once-weekly, triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.”
  3. 3.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use. [...] Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that retatrutide will prove to be a safe and effective treatment for type 2 diabetes, obesity or other potential indications, that retatrutide will receive regulatory approval, or that Lilly will execute its strategy as expected.”
  4. 4.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.”
  5. 5.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “The initial TRIUMPH Phase 3 clinical development program is evaluating the safety and efficacy of retatrutide for the treatment of patients with obesity or overweight, moderate-to-severe obstructive sleep apnea and obesity, and knee osteoarthritis pain across four global registrational trials. The program, which began in 2023, enrolled more than 5,800 participants.”
  6. 6.
    Eli Lilly: Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
    “In this global registration trial, where 84.0% of participants had a baseline BMI of ≥35 kg/m², each dose of retatrutide (9 mg and 12 mg) met all primary and key secondary endpoints, delivering significant weight loss and improvements in pain and physical function at 68 weeks using both the efficacy and treatment-regimen estimands. For the co-primary endpoints, retatrutide lowered weight by up to an average of 28.7% (71.2 lbs) and reduced pain by up to an average of 4.5 points (75.8%) using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score.”
  7. 7.
    Eli Lilly: Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
    “For the primary endpoint, participants taking retatrutide 9 mg and 12 mg lost an average of 64.4 lbs (25.9%) and 70.3 lbs (28.3%), respectively. Those taking the 4 mg dose of retatrutide, with just a single dose escalation step, lost an average of 47.2 lbs (19.0%). [...] In a pre-specified blinded extension for those with a BMI ≥35, participants who continued on retatrutide 12 mg to 104 weeks lost an average of 85.0 lbs (30.3%).”
  8. 8.
    Eli Lilly: Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
    “Percent change in body weight at 80 weeks: -17.6% (-19.8 kg; -43.7 lbs; 4 mg); -23.7% (-26.7 kg; -58.9 lbs; 9 mg); -25.0% (-28.2 kg; -62.1 lbs; 12 mg) and -3.9% (-4.4 kg; -9.7 lbs; placebo) [...] Discontinuation rates due to adverse events were 4.1%, 6.9%, 11.3%, with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 4.9% with placebo.”
  9. 9.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “In TRIUMPH-2, all three studied doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and improved glycemic control at 80 weeks in adults with type 2 diabetes and obesity or overweight. Participants taking retatrutide 4 mg, 9 mg, and 12 mg lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%), and 49.6 lbs (20.8%), respectively, alongside A1C reductions of up to an average of 1.6%.”
  10. 10.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “In TRIUMPH-3, both studied doses of retatrutide (9 mg and 12 mg) delivered substantial weight loss in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Participants lost up to an average of 55.8 lbs (22.6%) at 80 weeks. In the study, major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both retatrutide and placebo arms. In pre-specified analyses for time to first occurrence of MACE, there were 44 MACE-5 (all-cause death, heart attack, stroke, heart failure event, or coronary revascularization) events observed in participants randomized to retatrutide (pooled 9 mg and 12 mg) and 52 events observed in those randomized to placebo, resulting in a hazard ratio of 0.82 (95.0% CI: 0.55 to 1.22). There were 27 MACE-3 (cardiovascular death, heart attack, or stroke) events in participants randomized to retatrutide and 23 in those randomized to placebo, resulting in a hazard ratio of 1.12 (95.0% CI: 0.64 to 1.96).”
  11. 11.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “Lilly is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.”
  12. 12.
    ClinicalTrials.gov: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
    “A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1) [...] The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1).”
  13. 13.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled “for research purposes” or “not for human consumption.” These products have been sold directly to consumers for human use with dosing instructions. The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”